ZD6126
 | |
 | |
| Identifiers | |
|---|---|
| |
| Synonyms | ANG 453; AZD 6126; N-Acetylcolchicinol dihydrogenphosphate |
| CAS Number |
219923-05-4  |
| PubChem (CID) | 9896434 |
| ChemSpider |
8072099  |
| UNII |
GBO3S6M9W7 |
| Chemical and physical data | |
| Formula | C20H24NO8P |
| Molar mass | 437.38 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
| (what is this?) (verify) | |
ZD6126 is a vascular-targeting agent and a prodrug of N-acetylcolchinol, related to colchicine.[1] It has shown promising results on tumors in mice.[2]
A phase I clinical trial identified gastrointestinal and cardiac effects as limiting dosing.[3] Two phase II clinical trials were started investigating ZD6126 in metastatic renal cell carcinoma and metastatic colorectal cancer.[4][5]
ZD6126 was being investigated by AstraZeneca as a vascular disrupting agent (VDA). However, the trials were halted, after it became apparent that ZD6126 was too cardiotoxic at the required doses.[6]
References
- ↑ ZD6126, National Cancer Institute summary
- ↑ Hisatsugu Goto, Seiji Yano, Helong Zhang, Yuka Matsumori, Hirohisa Ogawa, David C. Blakey and Saburo Sone (1 July 2002). "Activity of a New Vascular Targeting Agent, ZD6126, in Pulmonary Metastases by Human Lung Adenocarcinoma in Nude Mice". Cancer Research. 62 (13): 3711–3715. PMID 12097279.
- ↑ LoRusso Patricia M; Gadgeel Shirish M; Wozniak Antoinette; Barge Alan J; Jones Helen K; DelProposto Zachary S; DeLuca Pamela A; Evelhoch Jeffrey L; Boerner Scott A; Wheeler Catherine (2008). "Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors". Investigational new drugs. 26 (2): 159–67. doi:10.1007/s10637-008-9112-9. PMID 18219445.
- ↑ astrazenecaclinicaltrials.com
- ↑ ZD6126, National Institutes of Health summary
- ↑ Lippert John W. III (2007). "Vascular disrupting agents". Bioorganic & Medicinal Chemistry 15 (2): 605-615.
This article is issued from Wikipedia - version of the 9/9/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.